Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01396057 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

244

Enrollment

INDUSTRY

Sponsor class

Conditions

Visual Impairment
Macular Edema
Branch Retinal Vein Occlusion

Interventions

DRUG: Ranibizumab
OTHER: Dexamethasone Implant
OTHER: Sham injection

Sponsor

Novartis Pharmaceuticals